These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26965514)

  • 1. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.
    Atiq F; Broers AE; Andrews LM; Doorduijn JK; Koch BC; Van Gelder T; Versmissen J
    Eur J Clin Pharmacol; 2016 Jun; 72(6):719-23. PubMed ID: 26965514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
    Eskazan AE
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1537-1538. PubMed ID: 27558360
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
    Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
    Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.
    Bleyzac N; Kebaili K; Mialou V; Bertrand Y; Goutelle S
    Ther Drug Monit; 2014 Dec; 36(6):724-9. PubMed ID: 24739665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
    Manabe A; Kawasaki H; Shimada H; Kato I; Kodama Y; Sato A; Matsumoto K; Kato K; Yabe H; Kudo K; Kato M; Saito T; Saito AM; Tsurusawa M; Horibe K
    Cancer Med; 2015 May; 4(5):682-9. PubMed ID: 25641907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
    Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
    Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and pharmacokinetics of imatinib in pediatric patients.
    Suttorp M; Bornhäuser M; Metzler M; Millot F; Schleyer E
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):219-231. PubMed ID: 29076384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
    Vidal-Petiot E; Rea D; Serrano F; Stehlé T; Gardin C; Rousselot P; Peraldi MN; Flamant M
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):169-74. PubMed ID: 26795084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.
    Arora R; Sharma M; Monif T; Iyer S
    Cancer Res Treat; 2016 Jul; 48(3):1120-9. PubMed ID: 26875198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients.
    Xue L; Zhang WW; Ding XL; Zhang JJ; Bao JA; Miao LY
    Am J Med Sci; 2014 Dec; 348(6):448-54. PubMed ID: 25247760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
    Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
    Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.